Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.14
ANGO's Cash to Debt is ranked lower than
89% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. ANGO: 0.14 )
Ranked among companies with meaningful Cash to Debt only.
ANGO' s 10-Year Cash to Debt Range
Min: 0.07  Med: 7.97 Max: N/A
Current: 0.14
Equity to Asset 0.69
ANGO's Equity to Asset is ranked higher than
70% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ANGO: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
ANGO' s 10-Year Equity to Asset Range
Min: 0.06  Med: 0.87 Max: 0.94
Current: 0.69
0.06
0.94
Interest Coverage 3.54
ANGO's Interest Coverage is ranked lower than
86% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.48 vs. ANGO: 3.54 )
Ranked among companies with meaningful Interest Coverage only.
ANGO' s 10-Year Interest Coverage Range
Min: 1.19  Med: 12.23 Max: 74.68
Current: 3.54
1.19
74.68
F-Score: 4
Z-Score: 2.06
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.35
ANGO's Operating margin (%) is ranked lower than
64% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. ANGO: 0.35 )
Ranked among companies with meaningful Operating margin (%) only.
ANGO' s 10-Year Operating margin (%) Range
Min: -10  Med: 8.00 Max: 13.14
Current: 0.35
-10
13.14
Net-margin (%) -1.02
ANGO's Net-margin (%) is ranked lower than
63% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. ANGO: -1.02 )
Ranked among companies with meaningful Net-margin (%) only.
ANGO' s 10-Year Net-margin (%) Range
Min: -8.13  Med: 3.52 Max: 8.75
Current: -1.02
-8.13
8.75
ROE (%) -0.68
ANGO's ROE (%) is ranked lower than
63% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. ANGO: -0.68 )
Ranked among companies with meaningful ROE (%) only.
ANGO' s 10-Year ROE (%) Range
Min: -3.97  Med: 2.94 Max: 198.83
Current: -0.68
-3.97
198.83
ROA (%) -0.46
ANGO's ROA (%) is ranked lower than
61% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. ANGO: -0.46 )
Ranked among companies with meaningful ROA (%) only.
ANGO' s 10-Year ROA (%) Range
Min: -3.51  Med: 2.75 Max: 9.77
Current: -0.46
-3.51
9.77
ROC (Joel Greenblatt) (%) -1.81
ANGO's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. ANGO: -1.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16.13  Med: 23.35 Max: 44.35
Current: -1.81
-16.13
44.35
Revenue Growth (3Y)(%) 5.20
ANGO's Revenue Growth (3Y)(%) is ranked higher than
52% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ANGO: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANGO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 3.2  Med: 9.60 Max: 25.2
Current: 5.2
3.2
25.2
EBITDA Growth (3Y)(%) 3.70
ANGO's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ANGO: 3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANGO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -33.8  Med: 5.00 Max: 31.3
Current: 3.7
-33.8
31.3
EPS Growth (3Y)(%) -37.00
ANGO's EPS Growth (3Y)(%) is ranked lower than
90% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ANGO: -37.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANGO' s 10-Year EPS Growth (3Y)(%) Range
Min: -37  Med: 6.70 Max: 100
Current: -37
-37
100
» ANGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ANGO Guru Trades in Q2 2014

Jim Simons 92,000 sh (+36.20%)
Chuck Royce 839,013 sh (+8.60%)
Steven Cohen 41,300 sh (unchged)
Mario Gabelli 86,000 sh (-9.47%)
» More
Q3 2014

ANGO Guru Trades in Q3 2014

Paul Tudor Jones 13,824 sh (New)
Jim Simons 153,160 sh (+66.48%)
Chuck Royce 848,531 sh (+1.13%)
Mario Gabelli 86,000 sh (unchged)
Steven Cohen Sold Out
» More
Q4 2014

ANGO Guru Trades in Q4 2014

Jim Simons 371,546 sh (+142.59%)
Paul Tudor Jones 17,029 sh (+23.18%)
Mario Gabelli 83,000 sh (-3.49%)
Chuck Royce 688,331 sh (-18.88%)
» More
Q1 2015

ANGO Guru Trades in Q1 2015

Mario Gabelli 83,000 sh (unchged)
Paul Tudor Jones 13,133 sh (-22.88%)
Chuck Royce 510,303 sh (-25.86%)
Jim Simons 263,846 sh (-28.99%)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 24.21
ANGO's Forward P/E is ranked lower than
64% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.03 vs. ANGO: 24.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.03
ANGO's P/B is ranked higher than
88% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. ANGO: 1.03 )
Ranked among companies with meaningful P/B only.
ANGO' s 10-Year P/B Range
Min: 0.64  Med: 1.01 Max: 6.67
Current: 1.03
0.64
6.67
P/S 1.53
ANGO's P/S is ranked higher than
71% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. ANGO: 1.53 )
Ranked among companies with meaningful P/S only.
ANGO' s 10-Year P/S Range
Min: 1.03  Med: 1.79 Max: 5.62
Current: 1.53
1.03
5.62
PFCF 57.82
ANGO's PFCF is ranked lower than
78% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.93 vs. ANGO: 57.82 )
Ranked among companies with meaningful PFCF only.
ANGO' s 10-Year PFCF Range
Min: 8.87  Med: 40.03 Max: 285.43
Current: 57.82
8.87
285.43
POCF 22.27
ANGO's POCF is ranked lower than
58% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.33 vs. ANGO: 22.27 )
Ranked among companies with meaningful POCF only.
ANGO' s 10-Year POCF Range
Min: 8.43  Med: 21.44 Max: 241.18
Current: 22.27
8.43
241.18
Shiller P/E 115.82
ANGO's Shiller P/E is ranked lower than
89% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.27 vs. ANGO: 115.82 )
Ranked among companies with meaningful Shiller P/E only.
ANGO' s 10-Year Shiller P/E Range
Min: 33.31  Med: 51.65 Max: 146.38
Current: 115.82
33.31
146.38
Current Ratio 2.64
ANGO's Current Ratio is ranked higher than
55% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. ANGO: 2.64 )
Ranked among companies with meaningful Current Ratio only.
ANGO' s 10-Year Current Ratio Range
Min: 1.95  Med: 5.54 Max: 14.28
Current: 2.64
1.95
14.28
Quick Ratio 1.48
ANGO's Quick Ratio is ranked lower than
56% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. ANGO: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
ANGO' s 10-Year Quick Ratio Range
Min: 1.16  Med: 4.17 Max: 12.12
Current: 1.48
1.16
12.12
Days Inventory 135.02
ANGO's Days Inventory is ranked lower than
52% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.78 vs. ANGO: 135.02 )
Ranked among companies with meaningful Days Inventory only.
ANGO' s 10-Year Days Inventory Range
Min: 94.14  Med: 135.53 Max: 174.24
Current: 135.02
94.14
174.24
Days Sales Outstanding 58.55
ANGO's Days Sales Outstanding is ranked higher than
53% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. ANGO: 58.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANGO' s 10-Year Days Sales Outstanding Range
Min: 45.92  Med: 60.11 Max: 207.55
Current: 58.55
45.92
207.55

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.91
ANGO's Price/Projected FCF is ranked higher than
84% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. ANGO: 0.91 )
Ranked among companies with meaningful Price/Projected FCF only.
ANGO' s 10-Year Price/Projected FCF Range
Min: 0.54  Med: 0.87 Max: 1.09
Current: 0.91
0.54
1.09
Price/Median PS Value 0.86
ANGO's Price/Median PS Value is ranked higher than
73% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. ANGO: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
ANGO' s 10-Year Price/Median PS Value Range
Min: 0.62  Med: 1.03 Max: 2.85
Current: 0.86
0.62
2.85
Earnings Yield (Greenblatt) (%) -0.41
ANGO's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ANGO: -0.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANGO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.41  Med: 4.10 Max: 10.9
Current: -0.41
-0.41
10.9
Forward Rate of Return (Yacktman) (%) 0.28
ANGO's Forward Rate of Return (Yacktman) (%) is ranked lower than
72% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.07 vs. ANGO: 0.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANGO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -16.8  Med: 1.10 Max: 6.6
Current: 0.28
-16.8
6.6

Analyst Estimate

May15 May16 May17
Revenue(Mil) 357 363 375
EPS($) 0.59 0.64 0.72
EPS without NRI($) 0.59 0.64 0.72

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:UG2.Germany,
AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company is organized in two segments: Vascular and Oncology/Surgery. The Oncology/Surgery Division includes Radiofrequency Ablation (RFA) and NanoKnife product lines. This division also includes the microwave ablation technology products obtained through the acquisition of Microsulis Medical Ltd. The Vascular division manages Fluid Management, Venous, AngioVac, Angiographic, PTA, Drainage, Thrombolytic, Micro Access Kits, Dialysis, PICC and Port product lines. The Company's product include the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories. The devices are utilized together and allow clinicians to aspirate or inject contrast, saline, remove waste and monitor invasive blood pressures throughout the procedure. The venous products consist of our VenaCure EVLT laser system and Sotradecol. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of a extracorporeal bypass procedure for up to six hours. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. The micro access sets provide interventional physicians a smaller introducer system for minimally-invasive procedures. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. The NanoKnife Ablation System is for the surgical ablation of soft tissue. The NanoKnife Ablation System utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. The treated tissue is then removed by the body's natural processes in a matter of weeks, mimicking natural cell death. The Acculis Microwave Tissue Ablation (MTA) System complements the full range of ablative technologies. The Company competes with Boston Scientific Corporation; Cook Medical; Cordis Corporation, a subsidiary of Johnson & Johnson, Inc.; C.R. Bard; Medical Components, Inc., or Medcomp; Arrow International, a subsidiary of TeleFlex Medical; Smiths Medical, a subsidiary of Smiths Group PLC; Vascular Solutions; Covidien subsidiaries (Kendall, VNUS, EV3) and Merit Medical
» More Articles for ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 

More From Other Websites
Coverage initiated on AngioDynamics by KeyBanc Capital Mkts Jul 24 2015
AngioDynamics Q4 Earnings Meet, Sales Hit by Forex Woes - Analyst Blog Jul 17 2015
ANGIODYNAMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 17 2015
Edited Transcript of ANGO earnings conference call or presentation 16-Jul-15 8:30pm GMT Jul 16 2015
AngioDynamics reports 4Q loss Jul 16 2015
AngioDynamics reports 4Q loss Jul 16 2015
AngioDynamics Inc Earnings Call scheduled for 4:30 pm ET today Jul 16 2015
AngioDynamics Reports Fiscal 2015 Fourth Quarter and Full Year Financial Results Jul 16 2015
AngioDynamics Reports Fiscal 2015 Fourth Quarter and Full Year Financial Results Jul 16 2015
Q4 2015 AngioDynamics Inc Earnings Release - After Market Close Jul 16 2015
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of AngioDynamics, Inc.... Jul 13 2015
Will AngioDynamics (ANGO) Miss Q4 Earnings Estimates? - Analyst Blog Jul 13 2015
AngioDynamics to Report Fiscal 2015 Fourth Quarter and Full Year Financial Results Jul 02 2015
AngioDynamics to Report Fiscal 2015 Fourth Quarter and Full Year Financial Results Jul 02 2015
Edited Transcript of ANGO presentation 1-Jun-15 5:30pm GMT Jun 26 2015
AngioDynamics to Present at the Jefferies 2015 Healthcare Conference May 26 2015
AngioDynamics to Present at the Jefferies 2015 Healthcare Conference May 26 2015
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Civil Securities Claims Against... May 20 2015
AngioDynamics to Present at the UBS Global Healthcare Conference May 11 2015
AngioDynamics to Present at the UBS Global Healthcare Conference May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK